Last reviewed · How we verify
AZD 8529
At a glance
| Generic name | AZD 8529 |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients (PHASE2)
- AZD8529 Single Ascending Dose Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD 8529 CI brief — competitive landscape report
- AZD 8529 updates RSS · CI watch RSS
- AstraZeneca portfolio CI